Contact us
Client:
GluBio Therapeutics Inc
Challenge:
GluBio Therapeutics Inc, a biotech company focusing on Targeted Protein Degradation (TPD) drug discovery and development, routinely analyzed whole cell proteomes under varying conditions to identify ideal drug candidates. The complexity and specificity of their research required a highly accurate and versatile mass spectrometry service.
Solution:
Innomics' Mass Spec proteomics services offered the precision and flexibility GluBio needed. Tailored specifically to GluBio's requirements, Innomics' TMT proteomics assay became an integral part of their robust drug discovery platform.
Results:
Why Innomics?
Looking Ahead:
GluBio is enthusiastic about the future of TPD drug discovery and development. This innovative approach allows them to target previously 'undruggable' disease targets, opening new avenues in therapeutic development. The success with oncology-focused TPD research has paved the way for GluBio to expand into other areas, such as their emerging sickle-cell disease program. Innomics will offer a comprehensive TPD solution via proteomics analysis assay based on high-resolution mass spectrometry for protein degradation drugs.
Conclusion:
Innomics’ Mass Spec services have not only met but also elevated GluBio's drug discovery and development process. This collaboration is a strong demonstration of how state-of-the-art technology when paired with expert service and swift execution, can truly propel pharmaceutical research and development to new heights.